CSTL logo

CSTL Castle Biosciences, Inc.

NASDAQ Global Market · Medical - Diagnostics & Research · Healthcare

$32.86
-0.55 (-1.63%)

Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patient…

Market Cap: $1.01Bcastlebiosciences.com

Price

No data yet.

Social Signal Score

55
5d
—
30d
55
5 mentions
—
60d
54
10 mentions
—
90d
54
13 mentions
—
news: 13

Analyst Ratings

11 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 0Sell 0Strong Sell 0
Avg price target$38.75+17.9%
Low $35Median $38High $44
Current Consensus

Revenue

$102.89M+2712.33%
$3.66M$36.95M$70.25M$103.55M
Mar 2018Sep 2026

Analyst Estimates

FY2025
$-1.04
$-1.58–$-0.47
5 analysts
FY2026
$-0.82
$-0.84–$-0.80
6 analysts
FY2027
$-0.63
$-1.02–$-0.23
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Derek J. Maetzold
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
1,002
Beta
0.95
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
6.55
castlebiosciences.com